U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry MIXED
Molecular Formula C34H36N4O6
Molecular Weight 596.6728
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HEMATOPORPHYRIN

SMILES

CC(O)c1c(C)c2cc3nc(cc4nc(cc5nc(cc1n2)c(C)c5CCC(O)=O)c(CCC(O)=O)c4C)c(C)c3C(C)O

InChI

InChIKey=UJKPHYRXOLRVJJ-AMPAVEGJSA-N
InChI=1S/C34H38N4O6/c1-15-21(7-9-31(41)42)27-14-28-22(8-10-32(43)44)16(2)24(36-28)12-29-34(20(6)40)18(4)26(38-29)13-30-33(19(5)39)17(3)25(37-30)11-23(15)35-27/h11-14,19-20,36-37,39-40H,7-10H2,1-6H3,(H,41,42)(H,43,44)/b23-11-,24-12-,25-11-,26-13-,27-14-,28-14-,29-12-,30-13-

HIDE SMILES / InChI

Description

Hematoporphyrin (Photodyn), a porphyrin prepared from hemin, is used as a photosensitizer in photodynamic therapy. Photodynamic therapy is based on the use of light-sensitive photosensitizers. Photoactivation causes the formation of singlet oxygen, which produces peroxidative reactions that can cause cell damage and death. Hematoporphyrin was used as the therapeutic agent in patients with manic-depressive reactions and in patients with involutional melancholia. One of the last studies has shown, that Hematoporphyrin-Photodynamic therapy (PDT) combined with stent placement is an effective and safe treatment for extrahepatic cholangiocarcinoma (EHCC).

Approval Year

Unknown
149124
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Manic-depressive disease
9
Sources: DOI: 10.1176/ajp.90.6.1157
 Primary
Not Provided
511
Unknown

Approved Use

Unknown
Involutional melancholia
4
Sources: DOI: 10.1176/ajp.90.6.1157
 Primary
Not Provided
511
Unknown

Approved Use

Unknown
Primary
Not Provided
511
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Mitochondrial reactive oxygen species accelerate the expression of heme carrier protein 1 and enhance photodynamic cancer therapy effect.
2014-07
Interaction of porphyrins with human organic anion transporting polypeptide 1B1.
2009-11-10
YC-1-like potentiation of NO-dependent activation of soluble guanylate cyclase by derivatives of protoporphyrin IX.
2006-03
Photodynamic therapy: a new approach to prostate cancer.
2003-06
Low-density lipoprotein receptors in the uptake of tumour photosensitizers by human and rat transformed fibroblasts.
2002-01
[Whole bladder wall laser irradiation to prevent bladder cancer recurrence with intravesical HpD and ascorbic acid].
1997-11
Structural investigation of the complexation properties between horse spleen apoferritin and metalloporphyrins.
1996-03
Temperature-induced changes in fluorescence properties as a probe of porphyrin microenvironment in lipid membranes. 2. The partition of hematoporphyrin and protoporphyrin in mitochondria.
1995-10-01
Separation of lipoproteins, albumin and gamma-globulin by single-step ultracentrifugation of human serum. Application. I: Binding of hematoporphyrin to human serum and to albumin.
1995-04
Hematoporphyrin diethers--V. Plasma protein binding and photosensitizing efficiency.
1990
[Effects of quercetin on photosensitized oxidation of alpha-tocopherol in human blood cells in the presence of hematoporphyrin].
1990
The use of hematoporphyrin derivative (HpD) in the localization and treatment of transitional cell carcinoma (TCC) of the bladder.
1984
Detection and localization of In situ carcinoma of the bladder with hematoporphyrin derivative.
1982-09
Patents

Patents

JP2005506199A
4
JP2007178237A
4
JPH06135966A
4
JPS60201255A
4

Sample Use Guides

In Vivo Use Guide
Twenty-three patients with manic-depressive reactions were treated during the depressed phase with intramuscular and oral administration of hematoporphyrin hydrochloride for an average period of 50 to 6o days. Of this number five showed marked sustained improvement, six showed moderate sustained improvement, and six were generally benefited but the course of the psychosis did not seem to be positively affected. Six gave no favorable response. Seventeen patients of 23 can be said to have been definitely helped by the treatment
Route of Administration: Other
In Vitro Use Guide
Unknown
Name Type Language
HEMATOPORPHYRIN
MI   WHO-DD  
Common Name English
NSC-267084
Preferred Name English
Hemoporfin [WHO-DD]
Common Name English
PHOTODYN
Common Name English
HEMATOPORPHYRIN [MI]
Common Name English
2,4-BIS(1-HYDROXYETHYL)-1,3,5,8-TETRAMETHYL-5,7-PORPHINDIPROPIONSAEURE
Common Name English
21H,23H-PORPHINE-2,18-DIPROPANOIC ACID, 7,12-BIS(1-HYDROXYETHYL)-3,8,13,17-TETRAMETHYL-
Common Name English
NSC-59265
Code English
21H,23H-PORPHINE-2,18-DIPROPANOIC ACID, 7(OR 12)-(1-HYDROXYETHYL)-12(OR 7)-(1-METHOXYETHYL)-3,8,13,17-TETRAMETHYL-
Common Name English
Hematoporphyrin [WHO-DD]
Common Name English
HAEMATOPORPHYRIN
Common Name English
7,12-BIS(1-HYDROXYETHYL)-2,8,13,17-TETRAMETHYL-21H,23H-PORPHIN-2,18-DIPROPIONSAEURE
Common Name English
2,18-PORPHINEDIPROPIONIC ACID, 7,12-BIS(1-HYDROXYETHYL)-3,8,13,17-TETRAMETHYL-
Systematic Name English
HEMOPORFIN
Common Name English
HEMATOPORPHYRIN IX
Common Name English
7,12-BIS(1-HYDROXYETHYL)-3,8,13,17-TETRAMETHYL-21H,23H-PORPHINE-2,18-DIPROPANOIC ACID
Common Name English
Classification Tree Code System Code
LOINC 33626-3
Created by admin on Mon Mar 31 19:26:54 GMT 2025 , Edited by admin on Mon Mar 31 19:26:54 GMT 2025
Code System Code Type Description
EVMPD
SUB14072MIG
Created by admin on Mon Mar 31 19:26:54 GMT 2025 , Edited by admin on Mon Mar 31 19:26:54 GMT 2025
PRIMARY
NSC
267084
Created by admin on Mon Mar 31 19:26:54 GMT 2025 , Edited by admin on Mon Mar 31 19:26:54 GMT 2025
PRIMARY
EVMPD
SUB96359
Created by admin on Mon Mar 31 19:26:54 GMT 2025 , Edited by admin on Mon Mar 31 19:26:54 GMT 2025
PRIMARY
NSC
59265
Created by admin on Mon Mar 31 19:26:54 GMT 2025 , Edited by admin on Mon Mar 31 19:26:54 GMT 2025
PRIMARY
MERCK INDEX
m5941
Created by admin on Mon Mar 31 19:26:54 GMT 2025 , Edited by admin on Mon Mar 31 19:26:54 GMT 2025
PRIMARY Merck Index
CAS
553-11-7
Created by admin on Mon Mar 31 19:26:54 GMT 2025 , Edited by admin on Mon Mar 31 19:26:54 GMT 2025
SUPERSEDED
NCI_THESAURUS
C167224
Created by admin on Mon Mar 31 19:26:54 GMT 2025 , Edited by admin on Mon Mar 31 19:26:54 GMT 2025
PRIMARY
CHEBI
36162
Created by admin on Mon Mar 31 19:26:54 GMT 2025 , Edited by admin on Mon Mar 31 19:26:54 GMT 2025
PRIMARY
EPA CompTox
DTXSID901030645
Created by admin on Mon Mar 31 19:26:54 GMT 2025 , Edited by admin on Mon Mar 31 19:26:54 GMT 2025
PRIMARY
SMS_ID
100000077911
Created by admin on Mon Mar 31 19:26:54 GMT 2025 , Edited by admin on Mon Mar 31 19:26:54 GMT 2025
PRIMARY
PUBCHEM
11103
Created by admin on Mon Mar 31 19:26:54 GMT 2025 , Edited by admin on Mon Mar 31 19:26:54 GMT 2025
PRIMARY
RXCUI
5164
Created by admin on Mon Mar 31 19:26:54 GMT 2025 , Edited by admin on Mon Mar 31 19:26:54 GMT 2025
PRIMARY RxNorm
FDA UNII
HBT6M5H379
Created by admin on Mon Mar 31 19:26:54 GMT 2025 , Edited by admin on Mon Mar 31 19:26:54 GMT 2025
PRIMARY
ECHA (EC/EINECS)
238-450-7
Created by admin on Mon Mar 31 19:26:54 GMT 2025 , Edited by admin on Mon Mar 31 19:26:54 GMT 2025
PRIMARY
DRUG CENTRAL
3274
Created by admin on Mon Mar 31 19:26:54 GMT 2025 , Edited by admin on Mon Mar 31 19:26:54 GMT 2025
PRIMARY
CAS
14459-29-1
Created by admin on Mon Mar 31 19:26:54 GMT 2025 , Edited by admin on Mon Mar 31 19:26:54 GMT 2025
PRIMARY
WIKIPEDIA
HEMATOPORPHYRIN
Created by admin on Mon Mar 31 19:26:54 GMT 2025 , Edited by admin on Mon Mar 31 19:26:54 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of HEMATOPORPHYRIN
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966